[Bacteriologic, clinical and kinetic evaluation of cefmenoxime (SCE 1365) in the treatment of 68 cases of septicemia. A multicenter trial].

Abstract

Cefmenoxime (SCE 1365), a new broad-spectrum, third generation cephalosporin was used in the treatment of 68 patients with bacteremia. Cefmenoxime was given as monotherapy to 63 patients in a mean daily dosage of 3 g (range: 1 to 6 g). 63 successes were recorded. Results were inconclusive in the remaining five cases. General and biological tolerance of cefmenoxime was excellent.

• Authors: A Bryskier, J P Sollet, G Bleichner, J M Segrestaa, J M Guerin, J B Dureux, P Canton, P Veyssier, P Y Lallement, J Mottin
• Journal: Pathologie-biologie (Pathol Biol (Paris)) Vol. 32 Issue 5 Pt 2 Pg. 547-51 (Jun 1984) ISSN: 0369-8114 [Print] France
• Vernacular Title: Evaluation bactériologique, clinique et cinétique de la cefménoxime (SCE 1365) dans le traitement de soixante-huit septicemies. Essai multicentrique.
• PMID: 6087250 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cefmenoxime
• Cefotaxime

Topics

• Adult
• Aged
• Blood Bactericidal Activity
• Cefmenoxime
• Cefotaxime (analogs & derivatives, blood, therapeutic use)
• Female
• Humans
• Kinetics
• Male
• Middle Aged
• Sepsis (drug therapy, microbiology)